Jun Kim: This study uncovers the potential of CD4+ T cells to complement CD8+ T cells and NK cells
Jun Kim, Founder & CEO at MedSchool Mentor, shared on X about a paper shared by Bastian Kruse et al. published in Nature:
“Published in Nature (2023), Kruse et al. (Tüting lab) demonstrate that adoptively transferred CD4+ T cells alone—but not CD8+ T cells—can eradicate melanoma tumors completely lacking both MHC class I and II expression.
These findings challenge the current paradigm of cancer immunotherapy, which predominantly focuses on CD8+ cytotoxic T cells whose effectiveness is limited by MHC loss and immunosuppressive TME. Historically viewed merely as ‘helper’ cells, CD4+ T cells instead have a critical yet underappreciated capacity for antitumor immunity independent of CD8+ cells. Intriguingly, CD4+ T cells do not directly infiltrate tumors in the same way CD8+ T cells do. Rather, they profoundly reshape the tumor immune landscape by recruiting and functionally reprogramming myeloid cells. These myeloid cells mature into potent interferon-activated APCs and robust iNOS-expressing tumoricidal effectors.
This study uncovers exciting therapeutic opportunities by revealing the potential of CD4+ T cells to complement CD8+ T cells and NK cells, paving the way for innovative strategies against immune-evasive cancers.”
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
Authors: Bastian Kruse et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023